erevnon
Posted - 2 weeks ago
Goldman Sachs maintains Veracyte $VCYT at Buy and raises the price target from $34 to https://marketsblock.com/stock-upgrades-and-downgrades/
IN0V8
Posted - 2 weeks ago
$VCYT Opportunity Leerink Partners raises target price to $50 from $40
Shlobby
Posted - 2 weeks ago
$VCYT we gapping and going
Doozio
Posted - 2 weeks ago
$VCYT how can it be a Thursday 🐑 suck in if it’s gapping INTA 🧠⏰♾️?
StockConsultant
Posted - 2 weeks ago
$VCYT Veracyte stock, watch for a narrow range breakout above 35.33 at https://stockconsultant.com/?VCYT
Shlobby
Posted - 2 weeks ago
$VCYT look pretty damn good here.
JFDI
Posted - 2 weeks ago
$VCYT stage II
Doozio
Posted - 2 weeks ago
$VCYT 8/7 Druck prolly starts his pos on gap above 200d in da FUTUre of 🧠⏰ as NEXN week it gaps n goes again INTA 🧠⏰♾️
StockConsultant
Posted - 10/31/24
$VCYT Veracyte stock, watch for a top of range breakout above 35.38 at https://stockconsultant.com/?VCYT
Estimize
Posted - 10/28/24
Wall St is expecting 21.91% YoY revenue growth for $VCYT in Q3, down from 26.66% in Q2 [Reporting 11/06 AMC]
http://www.estimize.com/intro/
IN0V8
Posted - 1 month ago
$VCYT Opportunity Leerink Partners raises target price to $40 from $35
StockConsultant
Posted - 1 month ago
$VCYT Veracyte stock, watch for a range breakout above 35.33 at https://stockconsultant.com/?VCYT
xvakero
Posted - 09/30/24
New longs this morning: $WULF $VCYT $ACLX
insiderbuyingselling
Posted - 09/23/24
$VCYT new insider selling: 5173 shares. http://insiderbuyingselling.com/?t=VCYT
Sasnak
Posted - 2 months ago
$VCYT wow. The Decipher data looks great. Wonder when $DGX or LabCorp takes notice and buys them up?
DonCorleone77
Posted - 2 months ago
$VCYT Veracyte announces new data from Phase 3 STAMPEDE clinical trial Veracyte announced that new data from a phase 3 trial of the multi-center, randomized STAMPEDE clinical trial show that its Decipher Prostate Genomic Classifier is prognostic for clinical outcomes and predicts benefit from docetaxel in patients with metastatic prostate cancer. The findings were presented at the European Society for Medical Oncology 2024 Congress in Barcelona. These findings support Veracyte's plan to expand use of the Decipher Prostate test - currently widely used to guide care for localized prostate cancer - to patients with metastatic disease. Prostate cancer accounts for a fifth of all male cancer-related deaths globally and the number is expected to double over the next two decades. In the United States, it is the second-leading cause of cancer deaths among men, with more than 35,000 men expected to die of the disease in 2025.2 Most prostate cancer deaths occur in patients who first presented with advanced or metastatic disease. In the new study, researchers analyzed data for 1,523 patients with advanced or metastatic prostate cancer who were followed in the STAMPEDE trial for a median of 14 years. They found that higher Decipher Prostate test scores were associated with an increased risk of death in both groups. Additionally, among the 832 patients with metastatic disease, only those with higher Decipher Prostate scores received a significant survival benefit from the addition of docetaxel to ADT. These patients had a 36% reduction in risk of death with the addition of docetaxel as compared to those with lower Decipher scores who did not significantly benefit. Notably, docetaxel was beneficial in patients with higher Decipher Prostate scores regardless of whether they had high- or low-volume prostate cancer. This is important because current clinical practice favors use of docetaxel in patients with high- but not low-volume disease. Veracyte expects to begin offering the Decipher Prostate test to patients with metastatic prostate cancer in early 2025, after its anticipated reimbursement by Medicare. MolDX, a program that establishes Medicare coverage for advanced molecular diagnostic tests, recently issued a local coverage determination for molecular testing in patients with metastatic prostate cancer, providing what Veracyte believes is a pathway to coverage for its test.
Stock_Titan
Posted - 2 months ago
$VCYT New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
https://www.stocktitan.net/news/VCYT/new-data-presented-at-esmo-2024-show-that-veracyte-s-decipher-wtk6s4pcj6jg.html
themarker
Posted - 08/30/24
Cathie Wood and Ark Invest's trade activity from 2024/08/29 $MASS $MTLS $MYNA $TTD $VCYT
kiwitc2000
Posted - 08/27/24
$VCYT Commercial stage bio forming a new base. Next leg on breakout over $33??
Stocksrunner
Posted - 3 months ago
$VCYT, $RMTI, $SN, $GOLD, $GOOG Analyzing Key Technical Indicators and Chart Patterns https://stocksrunner.com/posts?id=1035
jaydilks
Posted - 3 months ago
$ARKW $VCYT $ZM and $VUZI are now essentially out of ARKW.
Aigner_Andreas
Posted - 3 months ago
#GoldenCross $VCYT at 32.85 R52 HiLo 100% T1Y 30 buy DIV N/A #Veracyte I #stocks #trading #finance #market
PenkeTrading
Posted - 3 months ago
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Veracyte Inc. Is that bullish or bearish? $VCYT #VCYT #nasdaq #tradingsignals #technicalanalysis
themarker
Posted - 3 months ago
Cathie Wood and Ark Invest's trade activity from 2024/08/14 $VCYT $VERV
insiderbuyingselling
Posted - 3 months ago
$VCYT new insider selling: 47845 shares. http://insiderbuyingselling.com/?t=VCYT
themarker
Posted - 3 months ago
Cathie Wood and Ark Invest's trade activity from 2024/08/13 $LAB $MTLS $VCYT $VERV
themarker
Posted - 3 months ago
Cathie Wood and Ark Invest's trade activity from 2024/08/12 $U $VCYT $VLD $VUZI $BEAM
kinderspiel
Posted - 3 months ago
$PBF volume 1.0 m $VCYT volume 1.0 m $AHR volume 986 k $GTLB volume 985 k $FRSH volume 975 k
themarker
Posted - 3 months ago
Cathie Wood and Ark Invest's trade activity from 2024/08/09 $VCYT $VUZI $ZM $BEAM $TDOC